2-Methyl-6-methylthio-indol | 57330-47-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-Methyl-6-methylthio-indol
• 英文别名: 2-methyl-6-methylsulfanyl-indole；2-Methyl-6-methylthioindole；2-methyl-6-methylsulfanyl-1H-indole
• CAS: 57330-47-9
• 化学式: C₁₀H₁₁NS
• 分子量: 177.27
• InChiKey: CRYMJTDIHBCBIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  41.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Methyl-6-methylthio-indol 在 4-二甲氨基吡啶 、 Oxone 、 三氟乙酸 、 [双(三氟乙酰氧基)碘]苯 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 生成 3-(4-fluoro-phenylsulfanyl)-6-methanesulfonyl-2-methyl-1H-indole
  参考文献：
  名称：

  Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors

  摘要：

  The introduction of 3-arylmethyl, 3-aryloxy and 3-arylthio moieties into a 6-methylsulfonylindole framework using rational drug design led to potent, selective COX-2 inhibitors having efficacy in a rat carrageenan air pouch model. Incorporation of a conformationally more rigid 3-aroyloxy substituent onto the 6-methylsulfonylindole scaffold led to selective, but considerably less potent COX-2 inhibitors. Variation of the hydrophilicity and size of the indole 2-substituent of 3-arylthio-6-methylsulfonylindole inhibitors led to modulation of the COX-2 human whole blood (HWB) potency and selectivity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.075
• 作为产物：
  描述：

  3-氨基茴香硫醚 在 sodium tetrahydroborate 、 三氟化硼 、 碘 作用下， 以 甲醇 、 二氯甲烷 、 苯 为溶剂， 生成 2-Methyl-6-methylthio-indol
  参考文献：
  名称：

  Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors

  摘要：

  The introduction of 3-arylmethyl, 3-aryloxy and 3-arylthio moieties into a 6-methylsulfonylindole framework using rational drug design led to potent, selective COX-2 inhibitors having efficacy in a rat carrageenan air pouch model. Incorporation of a conformationally more rigid 3-aroyloxy substituent onto the 6-methylsulfonylindole scaffold led to selective, but considerably less potent COX-2 inhibitors. Variation of the hydrophilicity and size of the indole 2-substituent of 3-arylthio-6-methylsulfonylindole inhibitors led to modulation of the COX-2 human whole blood (HWB) potency and selectivity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.075

文献信息

• Indole derivatives as anti-inflammatory agents
  申请人：——

  公开号：US20030130337A1

  公开（公告）日：2003-07-10

  This invention relates to compounds, which are generally anti-inflammatory and analgesic compounds, and which are represented by Formula I: 1 wherein A is a —CH 2 —, —O—, —S—, or —S(O)—; and the other substituents are as defined in the specification; or individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents

  本发明涉及一类化合物，通常为抗炎和镇痛化合物，其由以下式I表示：其中A为—CH2—、—O—、—S—或—S(O)—；其他取代基如规范中定义；或其个别异构体、异构体混合物和其药用可接受盐。该发明还涉及含有这类化合物的药物组合物以及它们作为治疗剂的使用方法。
• [EN] HIGHLY ACTIVE SELF-SUFFICIENT NITRATION BIOCATALYSTS<br/>[FR] BIOCATALYSEURS DE NITRATION AUTO-SUFFISANTS HAUTEMENT ACTIFS
  申请人：UNIV FLORIDA

  公开号：WO2018081456A1

  公开（公告）日：2018-05-03

  The disclosure relates to the field of fusion proteins. In some aspects, the disclosure relates to artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes and uses thereof. In some aspects, the disclosure relates to compounds produced by artificial cytochrome P450 enzymes.

  该披露涉及融合蛋白的领域。在某些方面，该披露涉及人工融合蛋白，其中包括与还原酶酶相连的细胞色素P450酶，并其用途。在某些方面，该披露涉及由人工细胞色素P450酶产生的化合物。
• [EN] INDOLE DERIVATIVES AS COX II INHIBITORS<br/>[FR] DERIVES D'INDOLE UTILES COMME INHIBITEURS DE COX II
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003029212A1

  公开（公告）日：2003-04-10

  This present invention relates to indole derivatives of Formula (I); wherein A, Ar and R1 to R4 are as defines in the specification. The compounds are useful as a selective COX-II inhibitor and, therefore, may be used for the treatment of COX-II mediated diseases.

  本发明涉及公式（I）中的吲哚衍生物；其中A、Ar和R1至R4如规范中所定义。这些化合物可用作选择性COX-II抑制剂，因此可用于治疗COX-II介导的疾病。
• Artificial self-sufficient cytochrome P450s
  申请人：University of Florida Research Foundation, Incorporated

  公开号：US10138205B2

  公开（公告）日：2018-11-27

  The disclosure relates to the field of fusion proteins. In some aspects, the invention relates to artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes and uses thereof. In some aspects, the disclosure relates to compounds produced by artificial cytochrome P450 enzymes.

  本发明涉及融合蛋白领域。 在某些方面，本发明涉及由与还原酶连接的细胞色素 P450 酶组成的人工融合蛋白及其用途。 在某些方面，本发明涉及由人工细胞色素P450酶产生的化合物。
• Highly active self-sufficient nitration biocatalysts
  申请人：University of Florida Research Foundation, Incorporated

  公开号：US11078467B2

  公开（公告）日：2021-08-03

  The disclosure relates to the field of fusion proteins. In some aspects, the disclosure relates to artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes and uses thereof. In some aspects, the disclosure relates to corn-pounds produced by artificial cytochrome P450 enzymes.

  本公开涉及融合蛋白领域。在某些方面，本发明涉及由与还原酶连接的细胞色素 P450 酶组成的人工融合蛋白及其用途。在某些方面，本公开涉及由人工细胞色素P450酶生产的玉米蛋白。